Healthcare / Medical DevicesTechnical Analysis Guide

SYK Stock Analysis

Stryker Corporation

💡 Quick Answer

Across 4 APEX technical signals, SYK is currently split between bullish and bearish readings — 0 bullish, 0 bearish as of 2026-06-11. Run a live analysis to see the current composite score.

SYK is one of the highest-quality compounders in healthcare devices with ATR of 2-3%. It tends to trade at a premium to the sector due to MAKO adoption acceleration and its proven M&A track record.

MAKO Robotics: Primary growth engineRSI Behavior: Premium stock 50-72 rangeM&A Catalyst: Bolt-on deal history

Stryker is a leading medical technology company focused on orthopedic implants (knees, hips), surgical equipment, neurovascular devices, and emergency medical equipment (power cots, ambulances). Its MAKO robotic surgery system for joint replacement is the fastest-growing robotic platform in orthopedics, consistently taking market share from manual surgical techniques. Stryker is known for consistent double-digit EPS growth through a combination of organic growth and bolt-on acquisitions.

LIVE CHART·SYK. DailyPowered by TradingView

📊 Open SYK on TradingView ↗Affiliate link

Get live SYK signal analysis

APEX runs 8 signals on SYK in real time: RSI, MACD, Fibonacci, Volume, and more.

Analyze SYK Now →

Why Do Traders Watch SYK?

SYK is one of the highest-quality compounders in healthcare devices with ATR of 2-3%. It tends to trade at a premium to the sector due to MAKO adoption acceleration and its proven M&A track record. Post-earnings moves of 4-7% are common. Guidance raises, driven by MAKO procedure growth, tend to be the most reliable positive catalyst. The stock is relatively insensitive to drug pricing policy risk that plagues pharma names.

Is SYK a Buy Right Now? Current Signal Readings

📊MAKO RoboticsPrimary growth engine

MAKO robotic procedure counts (disclosed quarterly) are the single most important Stryker metric. Each new MAKO robot installed drives a recurring stream of implant and disposable consumable revenue for 10+ years. Quarterly MAKO install beats with procedure utilization growth above 10% have produced the most consistent SYK upside earnings reactions.

📊RSI BehaviorPremium stock 50-72 range

SYK's premium multiple sustains a higher RSI floor than the average healthcare stock. In bull markets, RSI holds above 55 and dips to 50-55 represent the best accumulation zones. RSI reaching 40 is a rare event and has historically marked a highly reliable longer-term entry point.

📊M&A CatalystBolt-on deal history

Stryker has made 40+ acquisitions over the past decade, consistently integrating them above their acquisition cost of capital. Each new deal announcement (typically in the $500M-$5B range) moves SYK 2-5% as investors price in deal value potential. Track corporate development activity via press releases and SEC filings.

📊Moving Average50-day primary support

SYK's 50-day moving average has been a reliable institutional support level. Volume confirmation is key: bounces at the 50-day with below-average volume (suggesting sellers are exhausted) have produced the highest-conviction SYK entry setups over the past five years.

📋 SYK Key Stats for Traders

⚡ATR (14-day)2-3% of price

📦Avg daily volume~2-3 million shares

🎯Key metricMAKO installs + procedure utilization

📅Post-earnings move4-7% typical

🔗 Related Stocks

MDT ISRG BSXZBH

Run a live SYK analysis

APEX combines RSI, MACD, Fibonacci, Volume, and 4 more signals into one composite score in under 30 seconds.

Analyze SYK Free →

📊 Advanced charting for SYK on TradingView ↗

💬 Frequently Asked Questions. SYK

QIs SYK a good stock to buy right now?

AWhether SYK is a buy depends on its current technical positioning. SYK is one of the highest-quality compounders in healthcare devices with ATR of 2-3%. It tends to trade at a premium to the sector due to MAKO adoption acceleration and its proven M&A track record. Post-earnings moves of 4-7% are common. Guidance raises, driven by MAKO procedure growth, tend to be the most reliable positive catalyst. The stock is relatively insensitive to drug pricing policy risk that plagues pharma names. Run a live APEX analysis at apexstockintel.com to see the current composite score, RSI, and MACD signals. Updated every trading day.

QWhat are the most important technical signals for SYK?

AThe four key signals for SYK are: MAKO Robotics (Primary growth engine). MAKO robotic procedure counts (disclosed quarterly) are the single most important Stryker metric. Each new MAKO robot installed drives a recurring stream of implant and disposable consumable revenue for 10+ years. Quarterly MAKO install beats with procedure utilization growth above 10% have produced the most consistent SYK upside earnings reactions.. RSI Behavior (Premium stock 50-72 range). SYK's premium multiple sustains a higher RSI floor than the average healthcare stock. In bull markets, RSI holds above 55 and dips to 50-55 represent the best accumulation zones. RSI reaching 40 is a rare event and has historically marked a highly reliable longer-term entry point.. M&A Catalyst (Bolt-on deal history). Stryker has made 40+ acquisitions over the past decade, consistently integrating them above their acquisition cost of capital. Each new deal announcement (typically in the $500M-$5B range) moves SYK 2-5% as investors price in deal value potential. Track corporate development activity via press releases and SEC filings.. Moving Average (50-day primary support). SYK's 50-day moving average has been a reliable institutional support level. Volume confirmation is key: bounces at the 50-day with below-average volume (suggesting sellers are exhausted) have produced the highest-conviction SYK entry setups over the past five years.

QWhat is SYK's RSI telling traders right now?

ASYK's premium multiple sustains a higher RSI floor than the average healthcare stock. In bull markets, RSI holds above 55 and dips to 50-55 represent the best accumulation zones. RSI reaching 40 is a rare event and has historically marked a highly reliable longer-term entry point. APEX scores SYK's RSI as part of its 8-factor composite signal. Updated daily.

QHow does SYK behave technically compared to other Healthcare / Medical Devices stocks?

ASYK is in the Healthcare / Medical Devices sector. Stryker is a leading medical technology company focused on orthopedic implants (knees, hips), surgical equipment, neurovascular devices, and emergency medical equipment (power cots, ambulances). Its MAKO robotic surgery system for joint replacement is the fastest-growing robotic platform in orthopedics, consistently taking market share from manual surgical techniques. Stryker is known for consistent double-digit EPS growth through a combination of organic growth and bolt-on acquisitions. Key stats: ATR (14-day): 2-3% of price, Avg daily volume: ~2-3 million shares, Key metric: MAKO installs + procedure utilization, Post-earnings move: 4-7% typical.

QWhat MACD signals work best for SYK?

AMACD measures momentum direction via the relationship between two exponential moving averages. Bullish crossovers (MACD line crossing above the signal line) indicate increasing upward momentum, while bearish crossovers signal the opposite. APEX tracks SYK's MACD histogram direction daily.

OTHER STOCK GUIDES

Technology49

+−